In June 2008 AstraZeneca and Bristol - Myers Squibb submitted a new drug application for Onglyza in the United States and a marketing authorization application in Europe .
That product was named saxagliptin ( Onglyza ) ( Figure 6 ) .
In June 2008 AstraZeneca and Bristol - Myers Squibb submitted a new drug application for Onglyza in the United States and a marketing authorization application in Europe .
That product was named saxagliptin ( Onglyza ) ( Figure 6 ) .